Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

0.2800 +0.0200 (+7.69%)
Streaming Delayed Price Updated: 10:58 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Preview: Syros Pharmaceuticals's Earnings
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
SYRS stock results show that Syros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
From Syros Pharmaceuticals
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Syros to Participate in TD Cowen 44th Annual Health Care Conference
From Syros Pharmaceuticals
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
Is your portfolio is in dire need of making new all-time highs? A new economic cycle is to send these penny stocks with potential up. 
Via InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
From Syros Pharmaceuticals
Via Business Wire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Syros Pharmaceuticals
Via Business Wire
Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?
Syros Pharmaceuticals Inc (NASDAQ: SYRS) released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
From Syros Pharmaceuticals
Via Business Wire
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing. 
Via InvestorPlace
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.